Genmab — November 2015
-
Ang. studier til senstadie patienter ved jeg heller ikke med Bavarian, men der kører andre interessante studier (dog kun fase 1/2), fx Abraxane (taxane)+Opdivo (Nivolumab) https://clinicaltrials.gov/ct2/show?term=nivolumab+AND+breast+cancer&rank=1 eller Entinostat (HDAC inhibitor) + Opdivo + Yervoy https://clinicaltrials.gov/ct2/show?term=nivolumab+AND+breast+cancer&rank=2
-
Janssen har ambitioner om andre Genmab-succeser
Den første lægemiddelgodkendelse er i hus, men Genmabs amerikanske partner Janssen har ambitioner om mere på baggrund af selskabernes andet samarbejde, hvor man er på vej ind i en ny fase. Hastigheden kan ifølge porteføljeforvalter fra Danske Capital komme bag på omverdenen.
(medwatch.dk)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
